Breast Cancer Guide on CD-ROM Is Available

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 6 No 5
Volume 6
Issue 5

DENVER--The AMC Cancer Research Center, through its Center of Excellence in Health Communications, has developed The Personal Guide to Breast Cancer, a multimedia CD-ROM guide to breast cancer prevention, detection, treatment, and resources, designed to be understood by the average layperson.

DENVER--The AMC Cancer Research Center, through its Center of Excellencein Health Communications, has developed The Personal Guide to BreastCancer, a multimedia CD-ROM guide to breast cancer prevention, detection,treatment, and resources, designed to be understood by the average layperson.

"Audiovisual presentations with full-color photographs guide theviewer through the information, addressing common questions and concerns,"said Bob Baker, president and CEO of AMC.

It is available in English or Spanish, and for Windows or Macintosh.There is a version for home and office use ($29.95, order no. U7AAAO) anda touch-screen version for educational and public-use settings ($49.95,U7AAB8).

The guide is being marketed by Time Life, with a portion of the profitsgoing to AMC. Order by calling Time Life Customer Services at 1-800-846-3843.

Recent Videos
Breast cancer care providers make it a goal to manage the adverse effects that patients with breast cancer experience to minimize the burden of treatment.
Social workers and case managers may have access to institutional- or hospital-level grants that can reduce financial toxicity for patients undergoing cancer therapy.
Insurance and distance to a tertiary cancer center were 2 barriers to receiving high-quality breast cancer care, according to Rachel Greenup, MD, MPH.
Antibody-drug conjugates are effective, but strategies such as better understanding the mechanisms of action may lead to enhanced care for patients with cancer. Antibody-drug conjugates are effective, but strategies such as better understanding the mechanisms of action may lead to enhanced care for patients with cancer.
ADCs demonstrate superior efficacy vs chemotherapy but maintain a similar efficacy profile that requires multidisciplinary collaboration to optimally treat.
According to Aditya Bardia, MD, MPH, FASCO, antibody-drug conjugates are slowly replacing chemotherapy as a standard treatment for breast cancer.
Administering oral SERD-based regimens may enhance patients’ quality of life when undergoing treatment for ER-positive, HER2-negative breast cancer.
Gedatolisib-based triplet regimens may be effective among patients with prior endocrine resistance or rapid progression following frontline therapy.
Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.
Related Content